On the previous publication, they did not have all the data they have now. That is correct. So likely there were some challenges if they wanted to speculate further on positive aspects that might be challenged by reviewers. In the current instance, they actually already will have all the data including biomarkers. So they should be able to more definitively and more quickly get to answers that I suspect were not possible to arrive at in that earlier iteration where they had to make due with blind data.
I think it will be easier, but they may want to do an initial article on results and then do a further study in the deeper elements if this long and complex trial that will likely be used to justify DCVax as a potential general therapeutic cancer vaccine. I could be wrong. But I think they have a lot of resources being thrown at it this time. They all know it is urgent, whereas the previous article, they knew they had plenty of time. It is just a wide range of different circumstances this time and I do not think it suggests they will take any more time than is necessary to publish.
News 
Market Data 
Discover 
